^
Association details:
| Biomarker: | BRAF V600E |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug Class: | MAPK inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Clinical and pathologic factors associated with survival in BRAFV600E colorectal cancers.
Published date:
05/13/2020
Excerpt:
Durable responses to MAPK-targeted therapies (5/25) and immunotherapy (3/25) were noted in the favorable group….Pts with BRAFV600E mCRC can achieve excellent long-term survival which belies conventional context and is driven by locoregional and systemic treatment options alike.
DOI:
10.1200/JCO.2020.38.15_suppl.4047
